We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori.
- Authors
Yang, Tiankuo; Liu, Bowen; Zhou, Junpeng; Shen, Yalin; Song, Xiaona; Tang, Xiaoqiong; Benghezal, Mohammed; Marshall, Barry James; Tang, Hong; Li, Hong
- Abstract
Background The aim of this study was to evaluate the rifamycin cross-resistance in Helicobacter pylori , and whether the use of rifampicin E-test strips to screen H. pylori rifabutin resistance is appropriate. Methods A total of 89 H. pylori isolates were included. Rifampicin minimum inhibitory concentrations (MICs) were obtained by E-test, while the MICs for rifapentine, rifaximin, and rifabutin were determined by agar dilution method. The rifamycin resistance rates based on different breakpoints were compared. Isolates with high-level rifampicin resistance were subjected to whole-genome sequencing. Results A wide distribution of MICs (mostly in the range 0.125–8 mg/L) was observed for rifampicin, rifapentine, and rifaximin. Using MIC >1, ≥ 4, and > 4 mg/L as the breakpoints, resistance rates to rifampicin/rifapentine/rifaximin were 60.4%/48.3%/38.2%, 28.1%/25.8%/23.6%, and 15.7%/16.9%/7.9%, respectively. However, the rifabutin MICs of all the tested H. pylori isolates were extremely low (≤0.016 mg/L). Applying MIC ≥ 0.125 mg/L as the breakpoint, rifabutin resistance was nil. No mutation was found in the rpoB gene sequences of the 2 isolates with high-level rifampicin resistance. Conclusions There is a lack of cross-resistance between rifabutin and other rifamycins in H. pylori. The use of rifampicin E-test to predict H. pylori rifabutin resistance is inappropriate.
- Subjects
HELICOBACTER pylori; RIFAMPIN; RIFAXIMIN; RIFAMYCINS; NUCLEOTIDE sequencing
- Publication
Journal of Infectious Diseases, 2022, Vol 226, pS479
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiac417